Historical Context

It has long been recognized that long QT syndrome (LQTS) is a clinical entity with a significant risk of SCD. When analyzing retrospective Holter monitor strips, Algra et al first recognized that short Q-T intervals had an increased risk of SCD. Gussak and associates were the first to propose SQTS as a unique clinical entity in a case series of three patients from one family with similar electrocardiogram (ECG) findings in the setting of atrial and ventricular arrhythmias.¹ In 2003, the definitive link was demonstrated between SQTS and SCD. Gaita et al studied several members of two families who exhibited Q-T intervals less than 280 ms and presented with syncope, palpitations, and a family history of SCD.²

EPS confirmed short atrial and ventricular refractory periods consistent with increased vulnerability to AF and VF.

Pathophysiology

Ion channels are essential in modulating the electrical gradient across myocardial cells in the process of depolarization and repolarization. Depolarization is modulated primarily through sodium and calcium channels, which allow an inward current into the cell.

Repolarization currents are mediated through potassium channels that allow ions to exit the cell and restore the negative transmembrane potential. The underlying basis of the SQTS is a gain of function abnormality of the potassium channel leading to a shortening of the action potential duration (APD), refractory period, and Q-T interval.

Furthermore, the shortening of the refractory period is heterogeneous within the myocardial cells, leading to nonuniform dispersion of refractoriness.³ This, in turn, may lead to VF through the mechanism of wavebreak through re-entry initiation, wavelet formation and, ultimately, fibrillation.^3–5

Molecular Genetics

SQTS is a genetically heterogeneous disease characterized by at least three different gene mutations of potassium channels involved in repolarization.

The KCNH2 gene, or HERG, encodes a transmembrane protein responsible for the rapidly activating delayed rectifier potassium channel I_Kr. Two missense mutations have been described that lead to “gain in function” and shortening of the APD leading to SQT1.^6,7 This potassium channel is the most commonly implicated in LQTS as well.

The KCNQ1 gene encodes the ion channel responsible for the slowly activating delayed rectifier potassium channel I_Ks. A missense mutation in the KCNQ1 gene results in accelerated activation kinetics consistent with a gain of function in the outward current. This mutation also leads to shortening of the APD and is considered the sporadic form of SQTS, called SQT2.^8,9

The KCNJ2 gene encodes for a protein responsible for the inward potassium rectifier current (I_K1). A mutation in this gene generates electrical currents that do not decrease to the extent of normal potassium channels. This corresponds to the end of phase 3 of repolarization, leading to acceleration of late repolarization, thereby shortening the APD. This mutation leads to a unique ECG finding of asymmetric tall T waves with a rapid descending portion that is now called SQT3.¹⁰

The three different mutations identified to date are all linked to potassium channels that alter currents at different points in the cardiac action potential. Mutations leading to loss of function in the KCNQ1, KCNH2, and KCNJ2 genes are also involved in LQT1, LQT2, and Andersen syndrome (LQT7), respectively. It has been difficult to classify the different forms of SQTS on the basis of genetic mutation because of the heterogeneity of the clinical syndrome and the inability to link clinical symptoms to a specific genotype.

Antzelevitch et al were the first to report loss-of-function mutations in genes encoding the cardiac L-type calcium channel to be associated with a familial SCD, in which a Brugada syndrome phenotype is combined with shorter than normal Q-T intervals. Among 82 probands with a clinically robust diagnosis of Brugada syndrome in the present registry, 6% (5 patients) presented with a shorter than normal Q-T interval, specifically mutations in CACNA1C and CACNB2b. Although the QTc intervals (330 to 360 ms) are longer than those encountered in KCNH2 and KCNQ1 mutations, they do overlap within the range found in patients with KCNJ2 mutations (SQT3) (Figure 64-1).¹¹

FIGURE 64-1 A, Ion channels are embedded in the membrane and allow the flux of ions in and out of the cells following voltage gradients. The sodium-calcium (Na⁺/Ca²⁺) exchanger (red) is electrogenic because it transports three sodium ions for each calcium ion across the surface membrane. B, Ionic currents and their corresponding genes. The generation of electrical activity by the different ionic currents will generate the cardiac action potential. Top, Three depolarizing currents. Middle, A ventricular action potential. Bottom, Repolarizing currents. Mutations in KCNJ2, which affects the I_K1 current, result in the third form of short QT syndrome. Mutations in KCNH2/KCNE2, affecting the I_Kr current, result in the syndrome’s first form. Mutations in KCNQ1/KCNE1, affecting the I_Ks current, result in the second form.

(From Brugada R, Hong K, Cordeiro JM, Dumaine R: Short QT syndrome, CMAJ 173[11]:1349–1354, 2005.)

Clinical Manifestations

SQTS has been characterized by major and minor cardiac events or symptoms. Major events include SCD, syncope, and VF. Minor events include palpitations, lightheadedness or dizziness, and paroxysmal AF. SCD is the most frequent first symptom and first clinical presentation. Most patients have a significant family history of SCD, occurring in relatives with a variable age distribution, ranging from 3 months to 70 years. The mean age of diagnosis is 30 years.¹² It has been suggested that sudden infant death syndrome may, in some cases, be attributed to SQTS.^12,13